X4 Pharmaceuticals (XFOR) Stock Statistics & Valuation Metrics

X4 Pharmaceuticals has a market cap or net worth of $373.51M. The enterprise value is $242.34M.

X4 Pharmaceuticals has 94,319,695 shares outstanding. The number of shares has decreased by -2.65% in one year.

X4 Pharmaceuticals’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -32.70%.

The current PE Ratio of X4 Pharmaceuticals is ―. X4 Pharmaceuticals’s PEG ratio is 0.03.

In the last 12 months, X4 Pharmaceuticals had revenue of 35.11M and earned -79.20M in profits. Earnings per share was -1.87.

In the last 12 months, operating cash flow was -92.85M and capital expenditures 19.60M, giving a free cash flow of -73.25M billion.

X4 Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

X4 Pharmaceuticals upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).

X4 Pharmaceuticals as a current ratio of 10.16, with Debt / Equity ratio of 45.86%

In the past 12 months, X4 Pharmaceuticals has paid 41.00K in taxes.

X4 Pharmaceuticals EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.33.

X4 Pharmaceuticals has $233.72M in cash and marketable securities with $77.25M in debt, giving a net cash position of $156.47M billion.

Gross margin is 79.44%, with operating margin of -247.44%, and net profit margin of -225.55%.

The average price target for X4 Pharmaceuticals is $11.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy